Patents Examined by Sergio Coffa
  • Patent number: 10433576
    Abstract: A method of alleviating symptoms of, or treating, pancreatic beta-cell damage in a subject includes a step of identifying a subject having pancreatic beta-cell damage. Multiple cycles of a diet protocol are administered to the subject. The diet protocol includes administering of a fasting mimicking diet and a re-feeding diet where the fasting mimicking diet is provided for a first time period and the re-feeding diet is provided for a second time period.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: October 8, 2019
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Chia-Wei Cheng
  • Patent number: 10434149
    Abstract: A method of promoting hemostasis in a subject in need thereof includes administering to the subject a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, wherein the peptides include a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and an active platelet GPM-Ma-binding peptides (GBPs).
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: October 8, 2019
    Inventors: Anirban Sen Gupta, Christa Pawlowski
  • Patent number: 10429129
    Abstract: Methods for preparing dried pellets of biological materials are described. The pellets can have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a solid surface followed by microwave vacuum drying the frozen droplets. These methods are useful for preparing dried pellets having a high concentration of a desired biological material, in particular a therapeutic protein or vaccine, and which have a faster reconstitution time than lyophilized powder cakes prepared in vials.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: October 1, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Jessica Sinacola, Rebecca Lizzano
  • Patent number: 10426820
    Abstract: A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 1, 2019
    Inventors: Anirban Sen Gupta, Christa Pawloski
  • Patent number: 10414808
    Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 17, 2019
    Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
  • Patent number: 10416170
    Abstract: The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 17, 2019
    Assignee: OXPROTECT GMBH
    Inventors: Beate Kehrel, Martin Brodde
  • Patent number: 10406200
    Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 10, 2019
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Roland R. Arnold, David C. Henke
  • Patent number: 10406204
    Abstract: The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 10, 2019
    Inventors: Sun-Chang Kim, Ju Ri Shin, Ki Jung Lim, Da Jung Kim, Young Woong Lee, Su A Jang, Bong Hyun Sung
  • Patent number: 10400018
    Abstract: Isolated tau peptides, and compositions comprising the peptides are disclosed. Further provided are antibodies specific for an isolated tau peptide. Methods of using the isolated tau peptide in diagnostic and treatment including using a pharmaceutical composition comprising the isolated tau peptide for stimulating an immune response in an individual to a tau peptide, and methods of using antibodies in detection, diagnosis, and treatment of disorders including a tauopathy are further provided.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 3, 2019
    Assignee: iPierian, Inc.
    Inventors: Irene Griswold-Prenner, Graham Parry, Tony SangYoung Byun
  • Patent number: 10363282
    Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 30, 2019
    Assignees: Board of Regents of The University of Nebraska, San Diego State University Research Foundation
    Inventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
  • Patent number: 10357539
    Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of Princeton University, Wisconsin Alumni Research Foundation
    Inventors: Yibin Kang, Yongna Xing, Liling Wan, Feng Guo
  • Patent number: 10351599
    Abstract: Described herein are anti-microbial peptides having enhanced activity and transport.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 16, 2019
    Assignee: Tensive Controls, Inc.
    Inventor: Kenneth Allen Gruber
  • Patent number: 10351601
    Abstract: The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptides. Compounds of the invention can be used to treat a variety of clinical conditions, including but not limited to, cancers, pulmonary fibrosis, HIV infection, rheumatoid arthritis, and other immune disorders. In addition, compounds of the invention can also be used in stem cell therapy.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: July 16, 2019
    Assignee: Mainline Biosciences
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 10351608
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 16, 2019
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Patent number: 10322188
    Abstract: This invention is about a cell-penetrating drug carrier and the application thereof. The mentioned cell-penetrating drug carrier can approach the target cell through using a proper recognizable sequence, so that the cell-penetrating drug carrier can be used to specifically delivery wanted drug to target cell. Through carrying wanted drug into the cytoplasm of the target cell by cell-penetrating peptide, the drug accumulation volume in the target cell can be efficiently increased. Preferably, through using proper bioinert polymer, the cell-penetrating peptide and the recognizable sequence can be kept from been digested before approaching the target cell.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 18, 2019
    Inventors: Ruoh-Chyu Ruaan, Ching-Wei Tsai, Chuan-Hui Lu, Yung Chang
  • Patent number: 10322109
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: June 18, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sadasivan Vidyasagar, Paul Okunieff, Lurong Zhang
  • Patent number: 10294275
    Abstract: Site-selective functionalized glycopeptide antibiotics, methods of making and using are described herein. The compounds exhibit improved activity against methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-sensitive S. aureus (VSE), vancomycin-resistant enterococci (VRE), or combinations thereof. The compounds can be administered as the neutral free acid or free base or can be administered as a pharmaceutically acceptable acid-addition or base-addition salt. The compounds can be formulated with one or more pharmaceutically acceptable excipients to prepare pharmaceutical compositions. The compounds can be administered by a variety of routes of administration including enteral, parenteral, topical, or transmucosal.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 21, 2019
    Assignee: Yale University
    Inventors: Tejaskumar P. Pathak, Scott J. Miller
  • Patent number: 10293075
    Abstract: The invention relates to porous absorbent Composite Material, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides a hydrophilic Self-Dispersive, fragmentable and Bio-Absorbable Porous Composite foams, suitable for packing antrum or other cavities of the body, comprising of composite of polymers, which polymer preferably comprises —C(O)—O—; NH2/3+; —OH; —CH2OCH2C(O)O— groups as functional or —CH—O— (e.g. C2H4O; C6H10O5; C6H8O6); —CH—N—O— (e.g. C8H13NO5); O—C—C— (e.g. O—CH2-CH2); —C(O)N— groups in the backbone of the polymers e.g. gelatin, chitosan, collagen, alginate, polyvinyl alcohol, polyethylene glycol, keratin, cellulose.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: May 21, 2019
    Inventors: Rajan Datt, Ramadhar Kumar, Siddharth Pandey, Pallavi Shrivastava
  • Patent number: 10286029
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 14, 2019
    Assignee: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
  • Patent number: 10286031
    Abstract: The invention relates to compositions for synchronizing the time of insemination in an animal. More particularly, the invention relates to a process for manufacturing and stabilizing GnRH-containing compositions for use in synchronizing the time of insemination in an animal.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: May 14, 2019
    Assignee: UNITED-AH II, LLC
    Inventor: Mark E. Swanson